Roots' C$4.10-a-Share Go-Private Deal Likely to Go Through -- Market Talk
Dow Jones2026/08/21 13:370936 ET - Roots has agreed to go private in a buyout deal that TD Cowen analyst Brian Morrison calls the best offer the apparel retailer is likely to receive. Roots, a household brand in Canada, has agreed to be acquired by a consortium led by Marquee Brands and JM&A Design & Development for C$4.10 a share. This represents a 36% premium to its price right before Roots announced a strategic review in March. Morrison says that given that the company has undertaken "what we view as a full auction process," and the current proposal has the backing of its board, among other support, "we see a high probability of the transaction closing as proposed" in 4Q. The analyst downgrades the stock rating to sell from hold as a result. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
August 21, 2026 09:37 ET (13:37 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
Crypto prices
More
